Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 151 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: HDL Clear all

Conditions: Cardiovascular Disease
Interventions: Almonds; Other
Lead sponsor: Penn State University; Other
Eligibility: 30 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Gestational Diabetes, Hyperlipidemia
Interventions: Total Cholesterol, Triglyceride, HDL, LDL; Other
Lead sponsor: Baystate Medical Center; Other
Eligibility: 16 Years to 40 Years · Female only
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Type 2 Diabetes Mellitus
Interventions: pioglitazone; Drug
Lead sponsor: University of Miami; Other
Eligibility: 35 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Dyslipidemia
Interventions: Trilipix, placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 30 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Prediabetes, Diabetes, High Cholesterol/Hyperlipidemia, Obesity & Overweight, Triglycerides, HDL Cholesterol
Interventions: Bottarga, Comparator; Other
Lead sponsor: Cambridge Health Alliance; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Sommerville, Massachusetts

Conditions: Familial Hypoalphalipoproteinemia
Interventions: CER-001, Placebo; Drug
Lead sponsor: Cerenis Therapeutics, SA; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Severe Hypertriglyceridemia
Interventions: Olezarsen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 56
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Chula Vista, California + 51 more

Conditions: Obesity
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 20 Years to 80 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Dyslipidemia
Interventions: Atorvastatin, ABT335, ER Niacin; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes Mellitus
Interventions: Patient Activation, Provider Training, Quality Improvement, Community Outreach; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 6,209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 6
States / cities: Chicago, Illinois

Conditions: Metabolic Syndrome
Interventions: Pioglitazone, Placebo, Niacin ER, Aspirin; Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Coronary Heart Disease
Interventions: gemfibrozil, Placebo; Drug · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Up to 73 Years · Male only
Enrollment: 2,531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 1999
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Insulin Resistance, Hypertriglyceridemia
Interventions: Rosiglitazone, Fenofibrate, Weight Loss; Drug · Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 30 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Stanford, California

Conditions: Acute Myocardial Infarction
Interventions: CSL112, Placebo; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 1,267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 48
States / cities: Birmingham, Alabama • Huntsville, Alabama • Concord, California + 43 more

Conditions: Dyslipidemias
Interventions: Niacin, Placebo; Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Gut Microbiota
Interventions: Dietary Fiber, Placebo; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Davis, California

Conditions: Lipid Metabolism Disorders, Hypertriglyceridemia
Interventions: EPA, DHA; Drug
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years to 69 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Breast Cancer, Breast Tumors, Cancer of Breast
Interventions: Metformin, Atorvastatin, Breast surgery; Drug · Procedure
Lead sponsor: Columbia University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections, Hyperlipidemia
Interventions: oyster mushroom; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Sickle Cell Disease
Interventions: Niacin-ER, Placebo, L-NMMA, Acetylcholine; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Obese, Vitamin D Deficiency, Low HDL
Interventions: Vitamin D; Dietary Supplement
Lead sponsor: Xiang-An Li; Other
Eligibility: 5 Years to 18 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Metabolic Syndrome, Hyperlipidemia
Interventions: ProAlgaZyme; Drug
Lead sponsor: Health Enhancement Products, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Edina, Minnesota

Conditions: Psoriasis, Atherosclerotic Cardiovascular Disease, Obesity, Dyslipidemia, Cardiometabolic Diseases
Interventions: Niagen, Placebo; Dietary Supplement · Other
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Overweight, Obesity
Interventions: Whole egg, Yolk-free egg; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 45 Years to 70 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Davis, California

Search by objective public record fields.

Effects of Almonds on Cardiovascular Risk Factors

Lipid Metabolism in Gestational Diabetes

Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes

Study of Trilipix Effects on Lipids and Arteries

Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" Food

CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases

A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia

Evaluation of High-Density Lipoprotein in Obesity Study

Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study

Improving Diabetes Care and Outcomes on the South Side of Chicago

Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL

The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol

Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.

A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

Effect of Niacin on Transport of HDL and Relationship to Atherogenic Lipoproteins and Lipolysis

The Effects of Dietary Fiber on the Gut Microbiome and HDL Particles of Human Subjects

Differential Thrombogenesis by EPA and DHA Mediated by HDL

Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer

Antihyperlipidemic Effects of Oyster Mushrooms

Niacin to Improve Blood Flow in People With Sickle Cell Disease

Roles of Vitamin D and HDL in Obese Children

The Effects of ProAlgaZyme on HDL Cholesterol in Individuals With Metabolic Syndrome

Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis

HDL Lipidomic, Proteomic and Functional Changes in Women After Eating Eggs